Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Barbey, J.T.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Barbey, J.T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Drug-induced torsade de pointes: the perspectives of industry

J.T. Barbey*

Division of Chemical Pharmacology, Georgetown University, Washington, DC, U.S.A

* Correspondence: Jean T. Barbey, MD, Assistant Professor of Medicine and Pharmacology, Division of Clinical Pharmacology, Georgetown University, 3900 Reservoir Road, Washington, DC 20007, U.S.A.

Abstract

In 1996 the Committee for Proprietary Medicinal Products published their ‘Points to consider’ which have been used as unofficial guidelines by drug companies developing new pharmacologic compounds. Recommendaitons endorsed by the CPMP regarding hand measurement of the QT interval, QT dispersion, the Bazett QT interval correction for heart rate and the use of signal values for QTc changes compared to baseline are discussed in this paper.

Key Words: ‘Points to consider’ • QT interval measurements

References

  1. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR. Torsades de pointes occurring in association with terfenadine use. J Am Med Assoc. 1990;264:2788–2790[Abstract/Free Full Text]
  2. Woosley RL, Chen YC, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. J Am Med Assoc. 1993;269:1532–1536[Abstract/Free Full Text]
  3. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction pharmacokinetic and electrocardiographic consequences. J Am Med Assoc. 1993;269:1513–1518[Abstract/Free Full Text]
  4. Committee for Proprietary Medical Products (CPMP). Points to Consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. The European Agency for Evaluation of Medicinal Products. December 1997.
  5. McLaughlin NB, Campbell WE, Murray A. Comparison of automatic QT measurement techniques in the normal 12 lead electrocardiogram. Br Heart J. 1995;74:84–89[Abstract/Free Full Text]
  6. Surawicz B. Will QT dispersion play a role in clinical decision-making? J Cardiovasc Electrophysiol. 1996;7:777–784[Web of Science][Medline]
  7. Funck-Brentano C, Jaillon P. Rate-corrected QT interval: Techniques and limitations. Am J Cardiol. 1993;72:17B–22B[CrossRef][Medline]
  8. Hnatkova K, Malik M. ‘Optimum’ formulae for heart rate correction of the QT interval. PACE. 1999;22:1683–1687

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Barbey, J.T.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Barbey, J.T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?